ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1224

Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic

Audrea Chen1, Tala El Tal2, Asha Jeyanathan1, Holly Convery1, Stephanie Wong1, Linda Hiraki1, Deborah Levy1 and Andrea Knight1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada

Meeting: ACR Convergence 2023

Keywords: mental health, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of referrals to MH services. However, regular MH screens help identify patients who need MH care and engage them in follow-up. In the childhood-onset systemic lupus erythematosus (cSLE) clinic at The Hospital for Sick Children, a new MH screening and referral system was recently implemented. This project aims to describe MH screening results and assess patient satisfaction with their MH care in the cSLE clinic.

Methods: Patients followed in the cSLE clinic aged ≥12 received a MH screen with validated assessment tools for depression (PHQ-9) and anxiety (GAD-7). Referral to MH services (psychology, social work, psychiatry and adolescent medicine) was based on symptom severity (Fig.1) and discussion with the patient. All patients who completed the MH screen received a handout with free online MH resources. An anonymous survey to assess patient satisfaction with their MH care was sent to patients ≥8 weeks after their initial screen. Repeat screens were performed for patients after 6 months. 66 surveys were distributed to 100 eligible patients. Data were collected from January 2022 to May 2023.

Results: 153 MH screens were completed, 37 patients were screened twice and 2 patients were screened 3 times. Most patients (60%) had minimal or no symptoms of depression and anxiety (Fig. 2). About a third of patients had mild symptoms, 14% of patients had moderate to severe symptoms and 8 patients (5%) reported suicidal ideation (primarily passive) (Fig.2). 12 patients (11%) were referred to adolescent medicine, 4 (4%) to social work and 1 (1%) to psychiatry. 28 satisfaction surveys were completed for a response rate of 42%. While 21% of patients felt that the MH screen brought up unwanted feelings, 100% found the MH screen to be a positive experience. 71% of patients were interested in follow-up or resources after their screen. 8 (28%) patients who completed the survey were referred to MH providers and were all satisfied with the services received. 5 patients had their appointment >4 weeks after referral, 2 patients had an appointment < 4 weeks after their referral and 1 patient had their appointment the same day as cSLE clinic. 2 patients seen >4 weeks after the referral felt that time to their MH appointment was too long. Suggested improvements to the MH process included making the physical space more welcoming and private, and asking about MH at every clinic visit.

Conclusion: While most patients had mild or no symptoms of depression and anxiety, MH screens detected 14% of patients with moderate to severe symptoms, and 16% were referred to MH services. MH screening was a positive experience and receiving MH resources was important to patients. Patients’ MH concerns were adequately addressed with MH services, although time to follow-up could be improved. Overall, the new MH screening process has identified important concerns for patients with cSLE and initiated appropriate referral to MH services with high rates of patient satisfaction. We hope to further improve this process based on patient feedback by changing the physical space and increasing the frequency of screens.

Supporting image 1

Figure 1. Pediatric rheumatology MH screen referral algorithm based on PHQ-9 and GAD-7 screening scores.

Supporting image 2

Figure 2. PHQ-9 and GAD-7 scores for depression and anxiety symptoms among the screened cSLE patients. Categories: None-minimal represents a score of 0_4, Mild 5-9, Moderate 10_14, Severe >15.


Disclosures: A. Chen: None; T. El Tal: None; A. Jeyanathan: None; H. Convery: None; S. Wong: None; L. Hiraki: None; D. Levy: None; A. Knight: Pfizer, 6.

To cite this abstract in AMA style:

Chen A, El Tal T, Jeyanathan A, Convery H, Wong S, Hiraki L, Levy D, Knight A. Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mental-health-screening-follow-up-in-the-childhood-onset-systemic-lupus-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mental-health-screening-follow-up-in-the-childhood-onset-systemic-lupus-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology